NeuroSense Other Current Liab from 2010 to 2024

NRSNW Stock  USD 0.15  0.11  42.31%   
NeuroSense Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2024. During the period from 2010 to 2024, NeuroSense Therapeutics Other Current Liabilities regression line of quarterly data had mean square error of 242.5 B and geometric mean of  51,519. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
1.9 M
Current Value
M
Quarterly Volatility
717.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NeuroSense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroSense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 186.9 K, Depreciation And Amortization of 21.6 K or Interest Expense of 379.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NeuroSense financial statements analysis is a perfect complement when working with NeuroSense Therapeutics Valuation or Volatility modules.
  
Check out the analysis of NeuroSense Therapeutics Correlation against competitors.
For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide.

Latest NeuroSense Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of NeuroSense Therapeutics Ltd over the last few years. It is NeuroSense Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeuroSense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

NeuroSense Other Current Liab Regression Statistics

Arithmetic Mean392,370
Geometric Mean51,519
Coefficient Of Variation182.81
Mean Deviation548,143
Median14,000
Standard Deviation717,279
Sample Variance514.5B
Range2M
R-Value0.75
Mean Square Error242.5B
R-Squared0.56
Significance0
Slope120,271
Total Sum of Squares7.2T

NeuroSense Other Current Liab History

2024M
20231.9 M
20221.2 M
2021558 K
202065 K

About NeuroSense Therapeutics Financial Statements

NeuroSense Therapeutics investors use historical fundamental indicators, such as NeuroSense Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NeuroSense Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities1.9 MM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NeuroSense Stock Analysis

When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.